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Abstract 
Genetic engineering is an emerging technology that offers the potential to prevent, treat, 
or cure genetic diseases. The technology can permanently alter the genome, providing an 
alternative therapy to drugs and surgery. Specifically, gene therapy is a promising treatment 
option for many incurable genetic diseases, such as cystic fibrosis and muscular cell dystrophy. 
Our project gives rise to a better understanding ofTALENs and its uses in the genetic 
engineering field. 
TALENs, transcription activator-like effector nucleases, are a genetic engineering 
teclmology that can be used for targeted gene modification. They are engineered proteins that 
can bind to specific sequences of DNA and induce a double-stranded break. The DNA sequence 
that the TALENs bind to is determined by the user; therefore the TALENs can be engineered to 
target specific DNA sequences that cause genetic diseases. We used TALENs within the model 
organism, nematode C. elegans, to explore their potential for use in gene therapy. By utilizing 
TALENs to introduce a lin-31 mutant into the genome of C. elegans we aim to advance the 
understanding ofTALENs as a genetic engineering tool and contribute to the research on the 
docking site ofLIN-31 in the Ras/MAPK signaling pathway. Our group was successful in 
creating the DNA that encodes for these TALENs proteins, providing a foundation for future 
student researchers to continue on the project. 
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Introduction and Significance 
Background/Motivation 
Genetic engineering is an emerging technology that offers the potential to permanently 
alter the genome of organisms. Gene therapy uses genetic engineering technologies to treat many 
incurable genetic diseases, such as cystic fibrosis and muscular cell dystrophy. It is an exciting 
tield because the technology can petmanently alter the genome, providing an alternative therapy 
to drugs and surgery. 
There are many ways by which genetic engineering can be achieved. One of the most 
common techniques is to use a nuclease to induce a double-stranded break in the genome. New 
genetic information can be insetted at this break site (an insertion mutation) or genetic 
infmmation can be deleted from the break site (a deletion mutation). After the genome is 
mutated, it is repaired either by non-homologous end joining (NHEJ) or by homologous 
recombination (HR). Non-homologous end joining allows the DNA to crash back together, while 
homologous recombination requires the use of template DNA (which contains the same sequence 
as the break site) to repair the broken ends. The variety in genetic engineering technology arises 
from the different types of mutations they induce after the double-stranded break in the genome 
and how this mutation is repaired. 
TALENs, transcription activator-like effector nucleases, are a genetic engineering 
technology that can be used for targeted gene modification. They are engineered proteins which 
can bind to specific sequences of DNA and induce a double-stranded break. This break is then 
repaired by either NHEJ or HR using template DNA. The user determines the DNA sequence 
that the TALENs binds to; therefore the TALENs can be engineered to target specific DNA 
sequences that cause genetic diseases, and therein lies its great potential as a therapeutic tool 
(Cermak). For our senior design project we used TALENs within the model organism, nematode 
C. elegans, to explore their potential for use in gene therapy. As a result of our research, we 
concluded that TALENS enables much more precise targeting of DNA sequences, and is 
therefore wotihy of continued testing and development. At the end of our report we will indicate 
the next steps that might be taken with this promising technology. 
Critique of Competing Technologies 
The established methods for gene therapy include retroviruses, zinc finger nucleases, and 
CRISPR. However, each ofthese technologies has significant drawbacks. As seen in Table 1, 
TALENs offers an exciting approach to gene therapy because it addresses the issues seen with 
the established methods for gene therapy. 
Table 1. A comparison ofTALENs to the current approaches to gene therapy 
Technology What it Does Drawbacks How T ALEN s Addresses 
these problems 
• Retroviruses • The virus can insert • Retroviruses • TALENs can be 
its DNA into the cutTently carmot be engineered to target 
host's genome engineered to specific DNA 
target specific sequences 
• The vitus's DNA DNA sequences 
permanently 
becomes patt of the • This can result in • TALENs gives the 
host's genome and undesired gene genetic engineer more 
is expressed using modification: the control over the gene 
the host's DNA retrovirus could modification; they will 
transcription and insert at a location not randomly modify 
translation in the genome that the genome 
machinery turns on an 
oncogene, causing 
cancer • Takes 5 days to 
engineer 
• Takes weeks or 
months to engineer 
• Zinc Finger • Engineered • Difficult to • The creators of this 
Nucleases proteins that can engineer teclmology have 
(ZFNs) target DNA developed a kit which 
sequences and provides a step by step 
induce a double • Have a significant protocol to engineer the 
stranded break failme rate TALENs 
• This break is then • Data has been 
repaired by 
Takes weeks or 
published showing the 
injecting DNA that • success ofTALENs 
acts as a template months to engineer 
forHR • Takes 5 days to 
engineer 
Technology What it Does Drawbacks How T ALEN s Addresses 
these problems 
• CRISPR • Engineered • Recently developed • T ALENs is a more 
proteins composed technology established approach to 
of a DNA binding gene therapy and has 
domain and a been studied in C. 
nuclease • High rate of off- elegans 
target effects 
• Break is then • Lower incidence of off-
repaired by target effects 
injecting foreign 
DNA 
A retrovirus is an RNA vitus that stores genetic information in the form of mRNA. The 
mRNA is then conve1ied into DNA with the use of the enzyme reverse transcriptase and can then 
be incorporated into the host cell's genome (Anson). Scientists have used retroviruses as vehicles 
for delivering corrected gene segments (Anson). This has shown that retroviruses have high 
efficiency when spreading their genetic information. However, a major problem with using 
retrovituses to con·ect genetic mutations is that they cannot be engineered to target specific DNA 
sequences and therefore could cause undesired gene modification. The retrovirus could insert 
DNA in a location within the genome that tums on an oncogene, causing cancer. Because ofthis 
drawback, new approaches to gene therapy were developed. 
Zinc finger nucleases (ZFNs) attempt to address the problems seen with retroviruses. 
ZFNs can be engineered to target specific sequences within the genome, as illustrated in Figure I 
below: 
Figure I: Structure of a Zinc Finger Nuclease ("What is"). 
As shown in Figure 1, after the ZFNs bind to the DNA, they are able to induce a double-
stranded break. The genome is then modified either through homologous recombination with an 
insetted plasmid or non-homologous end joining. ZFNs are composed of C2H2 zinc-finger 
motifs, which are the DNA binding domain and a Fokl nuclease, an enzyme that can cut DNA. 
Together these components create a targeted approach to genetic engineering and have been used 
successfully to disrupt genes in the model organism C. elegans (Wood). However, ZFNs have 
not become a widely used approach to genetic engineering because they are difficult to engineer 
and expensive to create. 
Recently developed approaches to gene therapy include CRISPR (Clustered Regularly 
lnterspaced Sh011 Palindromic Repeats) and TALENs (Transcription Activator-Like Effector 
Nucleases). Both of these technologies address the problems seen with retroviruses and ZFNs. 
T ALENs and CRISPR are similar to the zinc finger nucleases; they are engineered proteins 
composed of a DNA binding domain and a nuclease. The DNA binding domain in the CRISPR 
system is guide RNA derived from bacteria and is fused to the endonuclease Cas9 (Chen). This 
complex can then bind to and cut DNA. However, CRISPR is a recently developed technology 
and preliminary research has shown that it has more off-target effects, or binding in undesired 
locations. This is highlighted by a recently published study in which CRISPR was used to 
modify the genome of non-viable human embryos. Eighty-six embryos were used in this 
experiment, and only four contained the correct mutation (Cyranoski). Further data analysis 
indicated that many of the embryos used in the study contained oli-target mutations, meaning 
that CRISPR had modified the embryo's genome in an undesired location. 
We have chosen to use the TALENs approach to genetic engineering because they can 
be engineered to target specific DNA, have few limitations regarding the sequences they target, 
are easy to engineer, and have less off-target effects than CRISPR. 
Review ofTALENs Technology 
TALENs are engineered proteins comprised of transcription activator-like (TAL) 
effectors, the DNA binding domain of the protein, and a Fokl nuclease (Cermak). The TAL 
effectors are DNA binding proteins produced by bacteria in the Xanthomonas genus (Cermak). 
Because of this DNA binding capability, different TAL-effectors can be combined to create the 
DNA binding domain of the TALENs protein. The binding domain is then fi.Jsed to a Fokl 
nuclease, creating a protein that can target and induce a double stranded break at a specific 
location. TALENs have been used to successfully alter the genomes of C. elegans, zebrafish, 
tiuit flies, frogs, rats, and pigs (Joung). Most of these studies have used TALENs to induce 
knockout mutations, or mutations facilitated by non-homologous end joining, in the organism's 
genome (Joung). Specifically, our project will use TALENs to create a double stranded break, 
which will then be repaired through homologous recombination with a repair plasmid. Such 
homologous recombination is demonstrated in the image below through the process of "gene 
correction" or "gene addition". 
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Figure 2. Process of gene editing with a TALENs protein ("Custom"). 
As indicated in the graphic, the first step in using the TALENs technology is to identify 
the DNA sequence that will be altered. This sequence is then put into the TALENs software, a 
free online program developed by the creators ofTALENs. The user also inputs the location in 
the genome where the T ALENs should cut. The program then generates the DNA sequence for 
constructing T ALENs that will target the desired location in the genome. Once the template has 
been generated, the appropriate subunits from the T ALENs plasmid kit are used to create the 
TALENs DNA. This DNA is then transcribed into mRNA using an in vitro transcription kit. 
After the mRNA is created, it is microinjected into the C. elegans, along with the repair plasmid. 
The C. elegami' ribosomes then translate the TALENs mRNA into TALENs protein; this protein 
can then target the desired DNA sequence. Targeting occurs because the TALENs DNA binding 
domain contains only four types of repeating subunits, each corresponding to a specific 
nucleotide. This allows the user to customize the order of these subunits, creating two TALENs 
proteins that will bind to complementary strands of the desired DNA. Once the T ALEN s proteins 
bind, the Foki nuclease that is attached to the TALENs will induce a double stranded break in the 
DNA. 
In addition to making the TALENs DNA and mRNA, we will also construct a separate 
plasmid containing the desired mutant sequence that will also be microinjected with the mRNA. 
DNA repair machinery utilizes this plasmid as a template for homologous recombination. This 
results in an altered gene at its endogenous site within the genome. 
Statement of P1·oject Goal 
Our project focuses on engineering TALENs to alter the gene /in-31, an important gene 
in cell fate detennination in C. e/egans. Our goal is to create a modified version ofthe /in-31 
gene, which is then translated into a mutated LIN-31 protein. We hypothesized that this mutation 
will alter a putative Map Kinase docking site at the end of a Ras/Map Kinase signaling pathway. 
The success of this project will be analyzed by screening the microinjected C. e/egans for 
mutations. Both the constructed TALENs and the repair plasmid containing our altered sequence 
will be microinjected into C. e/egans. If the TALENs were successful, the nematode's progeny 
would contain the mutated version of our selected sequence. This mutation was hypothesized to 
create a visible mutant phenotype in a specific sensitized genetic background. 
Beyond scoring the phenotypes of the progeny of our TALENs C. e/egans, a cel-l assay 
will also be used to analyze the project. Pools of worms will be lysed in order to extract their 
DNA. This DNA will then be amplified using PCR or polymerase chain reaction. Cel-l, an 
enzyme that cuts mismatched DNA, will be extracted from celery, and when incubated with the 
PCR products from pools ofwmms, should reveal if the mutation is present. This DNA will also 
be sequenced to determine if the TALENs were successful in mutating the C. elegans genome at 
the desired location. 
Back-up Plan 
Due to the nature of scientific research, our design team ran into many issues that 
required troubleshooting and redoing experiments. Therefore, we were unable to complete the 
project in its entirety. However, we were able to create the TALENs DNA and have left a 
detailed lab notebook for future students to use as a guide to fiJrther explore the potential of 
TALENs as a genetic engineering tool. Our plan is to present our completed work and explore 
possible explanations as to what went wrong. 
Significance 
Not only does this project give rise to a better understanding of cell fate determination in 
C. elegans, but it also has the potential to increase our understanding of how transcription factors 
work at the end of other Ras/Map Kinase signaling pathways. Mutations in these pathways are 
found on approximately 70% of all human cancers (Sundaram). Therefore, successful 
completion of our project will give rise to a better understanding of the details of the working of 
this signaling pathway. 
With our project we will be able to gain a deeper understanding of the genetic 
engineering process. Because TALENs is a relatively new technology, our research has the 
potential to advance the general understanding ofT ALEN s and how they can be used in genetic 
engineering, especially as a research tool. These advancements will bring TALENs-based 
genetic therapy closer to the ultimate goal of using this technology to treat human genetic 
diseases. 
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1.0 Design and Construct 
Ras/MAPK Signaling Pathway 
One of the major goals of our project was to study a pathway known as the Ras/MAPK 
signaling pathway. This pathway is conserved among many organisms including humans. 
Ras/MAPK is involved in cell fate specification or the process by which cells determine their 
specific cell type. This is because activation of the pathway causes a phosphorylation cascade 
resulting in phosphorylated MAPK entering the nucleus and phosphorylating transcription 
factors. Phosphorylation is a means of communication because it alters structural conformation 
through the addition of a charged phosphate group. Transcription factors, or proteins that turn 
genes on or off, play an important role in cell development, including cell fate specification, 
depending on when they are activated or deactivated. 
Specifically, we studied the effect of Ras/MAPK on the LIN-31 transcription factor. The 
Miller lab has discovered a putative docking site on LIN-31 that tells MAP kinase where it 
should bind and therefore indicates that LIN-31 should be phosphmylated. Because C. elegans 
have been studied so extensively, we know they contain an anchor cell that utilizes the 
Ras/MAPK signaling pathway to communicate with neighboring cells and affect their 
development. If MAP kinase recognizes the docking site on LIN-31, it phosphorylates LIN-31 
and the cells receive the proper signal to develop normally. However, we wanted to confirm that 
the putative docking site is indeed a significant aspect of cell fate specification because of its role 
in the Ras/MAPK signaling pathway. Therefore, if we can create a mutation in the lin-31 gene at 
the location that codes for the docking site, we believe MAP kinase will be unable to recognize 
where it should bind and therefore not properly phosphorylate LIN-31. 
Within C. elegans, the anchor cell directs cells whether or not to become vulva cells. If 
all of the processes occur properly, one vulva develops. If the docking site and therefore proper 
phosphorylation of LIN-31 is dismpted, the cells do not receive the signal to develop into a vulva 
at the transcriptional activation level, causing a vulvaless animal. This is a convenient phenotype 
used to confirm our success because as hermaphrodites, vulvaless worms will internally fertilize 
oocytes causing an easily visible "bag ofwmms." 
1.1 Repair Plasmid 
Introduction 
In order to induce a specific mutation into the genome of C. elegans we first had to create 
a repair plasmid with the desired mutation in it. This repair plasmid served as a template for 
homologous recombination for the DNA strands and was incorporated into the genome of C. 
elegans. In our project we aimed to mutate the putative docking site on the LIN-31 protein. The 
potential docking site in the wild-type C. elegans contains arginine and lysine amino acids. Our 
repair plasmid contains the DNA that codes for two alanine amino acids. By incorporating the 
repair plasmid into the DNA we will disrupt this potential docking site and determine the effect 
on cell fate development. 
Arginine Lysine 
Alanine Alanine 
Figure 3. The original wild-type DNA and the DNA for the repair plasmid. The top strand of DNA shown is the 
DNA from wild-type C. elegans with the DNA for the docking site in orange. The bottom strand is from the repair 
plasmid DNA and contains the desired mutation. The DNA highlighted in purple is where our TALENs proteins 
bind. 
Details and Key Constraints 
Dr. Leilani Miller, Associate Professor in Biology at Santa Clara University, and her lab 
identified the site shown in Figure 3 as a potential docking site through analysis of consensus 
sequences. This segment of DNA was identified to be a potential docking site through consensus 
sequence analysis. This involves looking at DNA sequences of similar docking sites and 
identifYing the similarities in the sequences. More specifically, other studies looked at conserved 
sequences within MAP kinase targets until they determined sequences that act as docking sites 
by knocking them out and performing kinase assays. The Miller Lab received the information on 
what the docking site amino acid consensus sequences were, and then scanned lin-31 until that 
site was found. The DNA (pLM 545) for /in-31 with these docking site mutations was already 
created by Dr. Miller's lab. In order to create the desired repair plasmid we performed a TOPO 
cloning reaction, which is seen in Figure 4. 
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Figure 4. TOPO cloning reaction. The Topoisomerases create a break at their recognition site. The PCR product then 
incorporates into the plasmid at this break (New). 
TOPO cloning reactions use topoisomerases to uncoil and cut the plasmid DNA. This 
allows the new DNA to insett itself into the plasmid before the plasmid rejoins. In order to do 
this we amplified a short segment of DNA containing the mutations via a PCR reaction. By 
amplifying the DNA, we ensured that it would be in high concentrations and have A overhangs, 
making it ready to integrate when the topoisomerases cut the plasmid DNA. 
Detailed Design Description 
To amplify our DNA we used the PCR protocol from NEB entitled PCR Protocol for 
Phusion'ID High-Fidelity DNA Polymerase (M0530). PCR reactions use the ability of DNA to 
create a new strand from a complementary strand of DNA to create thousands of new copies of 
the same DNA. In order to do this, primers (shmt, complimentary sequences at the start and end 
of the desired fragment), a buffer, and nucleotides are added to the template DNA and put into a 
thermocycler. While in the thermocycler, the contents are heated to denature the DNA and then 
cooled and heated to promote replication in cycles, to amplify the DNA fragment. 
The TOPO cloning reaction uses blue/white selection to make screening for inse1tion 
easier. The Topoisomerases insert DNA within the LacZ gene on the plasmid. When the LacZ 
gene is disrupted, then no B-galactosidase enzyme is produced. This allows for an easy screening 
method because when grown on X -gal and IPTG plates the colonies with an intact LacZ and no 
insert will be blue. The colonies in which the LacZ was disrupted and the PCR product was 
inserted will be white. 
Detailed Supporting Analysis 
The TOPO cloning reaction is an established practice in the field of molecular biology 
and has been cited in over 20,000 papers (TOPO). 
Expected Results 
As stated earlier it is easy to screen for the success of the TOPO cloning reaction because 
it disrupts the LacZ gene. This process is called blue white selection. From this we expect to 
have white colonies, which indicate that the DNA was integrated into the plasmid. After this 
screening we willmn the DNA from the white colonies on gel electrophoresis, a technique used 
to determine the size of DNA. We expect to see a single band at around 1500 base pairs. When 
this is confhmed we will send the DNA out for sequencing to confirm that the mutation was 
inserted into the plasmid. 
Back-up Plan 
We will still use TALENs and disrupt the docking site via non-homologous end-joining. 
When the two ends of DNA crash back together in NHEJ, base pairs are lost and fhe gene is 
disrupted. 
Materials and Methods 
For our reactions we followed two widely used protocols to determine the materials and 
methods. We followed the PCR Protocol for Phusion® High-Fidelity DNA Polymerase (M0530) 
protocol for the PCR reaction. We then used Invitrogen's guide for the TOPO® TA Cloning® 
Kit for Sequencing. 
Results 
After performing the PCR and TOPO cloning reactions we observed approximately 50% 
white colonies. The white color implied that the LacZ gene had been dismpted and the desired 
DNA had been inserted into the repair plasmid. On the electrophoresis gel the DNA had a single 
band at the expected size. This gel is shown in Figure 5. We then confirmed that we had the 
correct DNA in the plasmid by sending the plasmid out for sequencing. The sequencing showed 
that we had a plasmid with the conect mutation in it. 
Figure 5: Electrophoresis Gel of repair plasmid. A single band around 1500bp was observed as expected. 
Discussion 
These results confirm that we created a repair plasmid containing the desired mutation we 
hope to induce into the C. elegans. After the TALENs and repair plasmid have been 
microinjected into the C. e/egans, it can be determined if the specific mutation was induced in 
the C. elegans progeny by comparing the sequencing results to the mutant sequence in the repair 
plasmid. This is an imp01tant step in the genetic engineering process, because it demonstrates 
T ALEN s ability to do gene replacement. 
1.2 TALENs DNA and mRNA 
Introduction 
TALEs are proteins discovered from the plant pathogen Xanthomomas. These TALE 
proteins are able to recognize and bind to specific sequences of DNA (Joung). 
Figure 6: TALE Binding protein ("TALEN"). 
Specifically, TALE proteins contain a DNA-binding stmcture made up of repeating loops 
of 33-35 amino acids that allow the protein to bind to a specific DNA sequence. Each loop varies 
with only two amino acids (Joung). This variety in amino acid loops determines which DNA 
base pair the TALE will bind to. This is seen in Figure 7. 
Figure 7: TALE binding loop bound to a specific DNA nucleotide (''TALENs for"). 
The users determine the order of the individual TALE loops (RVDs), and the order 
determines where the TALEN s protein will bind. Each RVD is specific to a single base pair of 
DNA. RVD NH binds to G, NI binds to A, HD binds to C, and NG binds to T (Joung). 
Therefore, the order in which the RVDs are linked together detem1ines where the TALENs will 
bind, allowing for targeted genome editing. It is necessary to design two TALENs proteins, one 
that can bind to the top strand of DNA and one that can bind to the bottom strand of DNA. The 
Foki nucleases of each of these TALENs then work together to create a double-stranded break in 
the DNA sequence; this is seen in Figure 8. 
LeftTALEN Rioht TALEN 
Figure 8: TALENs proteins (Sanjana). 
Figure 8 shows the two domains that make up the TALENs proteins, the DNA binding 
domain and the nuclease. This DNA binding domain of the TALENs protein is fused to a Foki 
nuclease. The TALE part of the protein recognizes and binds to the DNA sequence ofthe user's 
choosing, and the nuclease forms a dimer to create a double stranded break. Once this break is 
created, the cell is prompted to repair itself by homologous recombination with the template 
provided by the repair plasmid. 
Details and Key Constraints 
In order to create the double stranded break at the specific location, two TALENs 
proteins must be made. One TALENs binds to the top strand of DNA and the other binds to the 
bottom strand of DNA. The nucleases of these two proteins then dimerize and induce a donble 
stranded break at the specific site. In order to create the two TALENs proteins, first the DNA 
that encodes for these subunits must be put in the correct order. This is done in vitro. After the 
TALENs DNA is made, it must be transcribed into mRNA. This mRNA, along with the repair 
plasmid, can then be microinjected into the C. elegans. The ribosomes of the C. elegans will then 
translate the TALENs mRNA, creating TALENs proteins in vivo. These proteins can then target 
the specific DNA sequence and induce a double-stranded break, which can then be repaired by 
the repair plasmid. 
Detailed Design Description and Analysis 
Design of the TALENs DNA is done by choosing the specific DNA sequence where you 
would like to induce a double-stranded break, then customizing the TALEN s binding domain to 
target the chosen DNA sequence. 
All components necessary for making TALENs are supplied in the Golden Gate TAL 
Effector T ALENS Kit 2.0, which contains a library of plasmids. Each of these plasmids 
containing an RVD sandwiched between two type liS restriction enzyme recognition sites. 
Type liS restriction enzymes cut DNA at short distances from the recognition site, 
creating a break with a sticky end- single strand overhang as shown in Figure 9. 
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Figure 9: Type liS Restriction Enzymes ("Illustrations"). 
These sticky ends allow the subunits to be assembled in the correct order: the overhang 
for subunit 1 of the protein will only link together with the overhang of subunit 2. Therefore, 
when all the subunits are digested together with a type liS restriction enzyme and allowed to 
undergo a digestion and ligation reaction, all the different subunits are ligated together in the 
desired order. This allows for the design of a TALENs protein that will target the sequence of the 
user's choosing. 
After all of the different RVDs are linked up in the digestion and ligation reaction , the 
TALENs DNA plasmid has been created. This DNA is then transformed into E. coli. 
Transformation is a molecular biology technique that allows for the insertion of foreign plasmids 
into the bacteria. The bacteria then amplify the plasmid to create large quantities of it. 
Colony PCR allows for the analysis of DNA sequences, and allows us to detennine the 
success of our TALENs creation. In the colony PCR reaction the DNA is amplified and can then 
be analyzed by gel electrophoresis and DNA sequencing. Gel electrophoresis is a technique that 
allows for the determination of the size of a segment of DNA, and DNA sequencing allows for 
the determination of the exact base pair sequence of a segment of DNA. 
Results 
It was expected that our gel electrophoresis results would show a band which was 
approximately 1200 base pairs in length because our group knew the size of all the individual 
components which made up the T ALENs DNA. Our group was able to obtain our expected 
results, as seen in Figure 10. 
Figure 10. Gel Electrophoresis results of TALENs DNA. 
After detetmining that our TALENs DNA was the right size, our next step was to 
determine the RVDs had linked in the con·ect order. This was done by sending the TALENs 
DNA out for sequencing. Because our group knew the DNA sequence of each of the individual 
RVDs, we were able to determine what the DNA sequence of the TALENs DNA obtained from 
colony PCR should be. We compared the expected DNA sequence and the DNA sequence 
obtained from the sequencing company and found that our results matched the expected DNA 
sequence. This indicated we had been successful in creating TALENs DNA whose RVD 
components were linked up in the order we desired. 
Our group has successfully created the TALENs DNA and is currently finishing the final 
steps of preparing the TALENs DNA for microinjection. When creating the plasmids that 
contain the TALENs DNA, only 10 subunits can be linked together in one reaction. The DNA 
we are ereating contains 19 subunits. Therefore, creating the full length TALENs DNA plasmid 
is a two step process. The first step involves combining subunits 1-10 in one reaction and 
subunits 11-19 in another. This creates the two halves of the TALENs DNA. The second step 
combines these two halves together, creating a DNA plasmid containing the full length T ALENs 
DNA. Our group was able to successfully create the four halves ofTALENs DNA necessary for 
our project. 
Back-up Plan 
Our group's back-up plan was to repeat the experiment, troubleshooting various 
components of the reactions, until we were able to successfully create the TALENs DNA. This 
would allow us to optimize the process of creating the TALENs DNA until we could 
successfully create it. Additionally, we have maintained a detailed notebook for future student 
researchers to follow, which allows for the continuation of the project. 
1.3 Microinjection 
Introduction 
Once we have successfully transcribed our TALENs DNA into mRNA with the in vitro 
transcription kit, we will be microinjecting the mRNA along with our repair plasmid into the 
gonad of the C. e!egans. Microinjection is defined as ''the use of a glass micropipette to inject a 
liquid substance at a microscopic or borderline macroscopic level" (Evans). This can be seen in 
Figure II. 
Figure II: Microinjection into C. elegans. 
Details and Key Constraints 
The C. elegans are one millimeter in length and therefore the injection process must be 
precise. A high resolution-inve1iing microscope with a microinjecting device to hold the 
micropipette in place is used. 
Detailed Design Description and Analysis 
Once inside the gonad of the C. elegans, the developing oocytes will take up the DNA 
and mRNA, and their ribosomes should then translate the TALENs mRNA into TALENs 
protein. The TALENs protein can then target and bind to the desired sequence on the lin-31 gene 
and create a double stranded break at the potential docking site. The ends of our repair plasmid 
should be complementary to the break in the genome and hopefully integrate into the C. elegans 
DNA through homologous recombination. 
If the repair plasmid is able to successfully integrate into the genome at the created 
double stranded break, the C. elegans' progeny should have the mutated version of the lin-31 
gene. The docking site on LIN-31 will be altered, making MAP kinase unable to recognize it as a 
phosphorylation target. The surrounding cells will then not receive the correct signals and a 
vulva will not develop. Because C. elegans are hermaphrodites and contain both sex organs, the 
progeny will develop and be unable to escape through the vulva. We will then observe a "bag of 
worms," or an adult worm with live progeny inside, this is shown in Figure 12. 
Figure 12; Bag of worms phenotype. 
Results 
Unfmtunately, we were unable to reach this step in our experiment before June. 
However, once we are able to successfully create TALENs mRNA from our T ALENs DNA, we 
believe this process will be straightforward and easily accomplished. We should be able to obtain 
results fairly quickly because of the shmt maturation cycle of the C. elegans. 
1.4 Screening for Results 
Introduction 
If the activity of LIN-31 is disrupted, unspecified cells in C. elegans do not receive the 
signal to develop into vulva cells and the organism will display the vulvaless phenotype. This is 
a convenient phenotype to use to confirm our success because it is easily visible. As seen in 
Figure 13, it is easy to distinguish between vulvaless and wild type C. elegans. 
Figure 13: Comparison of C. elegans phenotypes (Rawat). 
It is expected that the C. elegans that were not mutated by T ALENs will display the 
wildtype phenotype, while the mutated C. elegans will display the vulvaless phenotypes. These 
phenotypes will be determined by visualizing the organisms under a dissecting microscope. 
A successful mutation will then be confirmed by analyzing the DNA of the vulvaless C. 
elegans. This will be done by sending out their lin-31 DNA for sequencing. The DNA sequence 
of a successful mutation will contain the repair plasmid sequence insetted at the cut site on lin-
31; this is shown in Figure 14. 
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Figure !4: DNA sequence containing the desired mutation of /in-31. 
Details and Key Constraints 
Each animal is injected and allowed to grow for several days on Nematode Growth 
Media plates at 20-25 degrees. After that time the injected C. elegans should have produced 
offspring that are now old enough to be screened for phenotypes under a dissecting microscope. 
The C. e!egans with the correct phenotype are picked and lysed for their DNA. This DNA is then 
amplified with PCR and sent out for sequencing. 
Detailed Design Description 
By mutating the lin-31 gene in C. elegans we are affecting the vulval cell development in 
the organisms. C. e/egans are hermapluodites and therefore able to fertilize internally. When this 
occurs in a vulvaless C. e/egan the progeny are unable to escape and therefore begin consuming 
the original organism. This results in the phenotype commonly referred to as a bag of worms. 
This can be seen above in Figures 12 and 13. 
Detailed Supporting Analysis 
C. e/egans have been studied extensively and shown to have many different mutant 
phenotypes. Due to their self-fertilization capabilities they allow us to study cell fate 
determination by their ability or inability to develop vulvas and the visible phenotype occurs as a 
result. The vulvaless phenotype has been induced through other methods of mutating the genome 
of C. elegans such as exposure to radiation. 
Expected Results 
For our results we would expect to see C. elegans with the vulvaless phenotype. When 
the DNA from these C. eiegans are sent out for sequencing we would expect them to contain the 
lin-31 sequence shown in Figure 14 that codes for the alanine amino acids in the place of the 
arginine and lysine residues in the potential docking site. 
Back-up Plan 
If the progeny do not display the expected phenotype, we will run a Cel-l assay. The Cel-
l assay allows us to screen many C. elegans, with any mutation, at one time. Cel-l is an enzyme 
isolated from celery that cuts mismatched DNA. We would expect that the pools of C. elegans 
that contain individual C. elegans with mutations would show mismatches when lysed and the 
lin-31 gene is amplified through PCR. The PCR product fi-om the pools of worms is then 
incubated with Cel-l, run on an agarose gel, and the fragment is cut. We would see three bands, 
indicating that at least one of the wmms in the original pool contains a mutation. The three bands 
are only present when the mutated DNA creates a mismatch with the wild type DNA. From 
there, individual worms can be mixed with wild type worms, lysed, amplified with PCR, and 
incubated with Cel-l to dete1mine which individual worms contain mutations. Then, these 
mutant PCR products can be sent for sequencing. 
Materials and Methods 
For this step we will require a dissecting microscope and the microinjected C. e/egans 
and their progeny. In order to isolate the DNA for sequencing from the C. e/egans the worms are 
placed in a buffer containing Proteinase K, and heated in the thermocycler. This lyses the worms, 
releasing their DNA, which is then used in a PCR reaction to amplify the docking-site coding 
fragment of the /in-31 gene. 
Results 
Until the repair plasmid and T ALENs are injected we cannot complete this step. However 
this step is straightforward and will take little time to complete. 
Discussion 
If this step is successful it will not only confirm that TALENs is an effective technology 
for genome editing, but also support the research done to prove that the sequence targeted in this 
experiment codes for a docking site on LIN-31. This has the potential to contribute to the 
research on TALENs as well as research on LIN-31 and the Ras/MAP kinase pathway. 
Summary and Conclusion 
T ALENs, transcription activator-like effector nucleases, are a genetic engineering 
technology that can be used for targeted gene modification. For our senior design project we 
used TALENs to explore their potential for use in gene therapy. Gene therapy is an exciting field 
as it provides the potential to cure many genetic diseases. Gene therapy offers the potential for a 
cure to these diseases because it can be used to permanently repair the genome. Specifically, our 
project with TALENs will provide a service to society as it will give rise to a better 
understanding of the technology and its uses as a genetic engineering research tool. 
Over the course of our senior year, we have been able to successfully construct T ALENs 
DNA that codes for a protein that will bind specifically and cut the genome at our desired 
location. We have validated the ability to create customizable DNA binding domains designed 
by the user. The materials and methods involved in creating T ALEN s are fairly common and 
straightforward. A majority of laboratories have all of the necessary facilities and knowledge to 
utilize this technology. Such accessibility is testament to the relevance and future of the TALENs 
technology. We have high hopes that our work will lead to further exploration ofTALENs at 
Santa Clara University and that researchers will continue to improve TALENs for its use in gene 
therapy. 
Engineering Standards and Realistic Constraints 
Health & Safety 
Current Concerns 
When evaluating the health and safety concems associated with the TALENs technology 
it is important to consider them in the context of our project as it stands currently and in the 
context of future applications in gene therapy. Currently our own safety is the greatest concern. 
While working with any toxic chemicals or dangerous microorganisms it is impmtant that we are 
always using good lab technique to protect ourselves and those in the lab around us. Hazards in 
our lab include ethidium bromide (a known carcinogen), E. coli bacteria, flammable chemicals, 
and UV light. It is impmtant that we always use the appropriate precautions such as wearing 
gloves and disposing of all materials properly. 
Future Concerns 
When considering the safety and risk involved with future treatments for patients using 
TALENs there are many. It is important that we cunently document all observations so that 
when the treatment is being tested in humans, we can provide them with as much information as 
possible. Informed consent requires that the patients and doctors know the risks involved with 
the treatment. In order to fully explain the risks, there has to be good documentation tlu-oughout 
the entire development, especially in regards to any adverse or unintended effects. While all 
clinical trials involve risk, it is important that all possible precautions are taken to minimize these 
risks before they are tested in humans. 
The need for precautions in using genetic engineering teclmologies is highlighted by a 
recent publication about targeted genome editing; specifically, CRISPR (a genetic engineering 
technology similar to TALENs) was used to edit the genome of non-viable human embryos 
(Liang) . This research team attempted to edit the gene that causes P-thalassacmia, a genetic 
mutation invo lved in blood disorders (Cyranoski). Eight-six embryos were used in this 
experiment, and only four contained the correct mutation (Cyranoski). 
Purther data analysis indicated that many of the embryos used in the study contained off-
target mutations, meaning that CRISPR had moclitiecl the embryo's genome in an undesired 
location. This is a major health and safety threat because these mutations could be harmful. This 
study highlights the health and safety concerns surrounding these genetic engineering 
teclm ologies because they do have the potential to mutate the genome in undesired locations. 
Therefore. further research needs to be done to ensure that these technologies only mutate the 
genome at a specific, targeted location, minimizing the health and safety risks associated with the 
technology. 
Social Considerations 
Introduction 
The ability to specifically target a desired location of the genome is an incredibly 
powerful tool with the potential to be developed for numerous applications. The application of 
gene therapy is an honorable one that aims to provide relief to victims of genetic disorders. 
Proponents argue that if we have the ability to prevent excruciating pain then we should be 
obligated to do so, while opponents believe gene therapy is a slippery slope to genetic 
enhancement. Whatever the case, many other considerations need to be taken into account that 
will ultimately affect social perceptions of gene therapy. For example, if gene therapy becomes a 
viable option in the future, should women be required to receive genetic screening? Is it wrong 
for a family to bring a child into the world if they know his or her life will be filled with 
suffering? This brings up the question of when exactly such testing should be performed. Also, if 
people or companies have the ability to alter a genome, are they creating new patentable life 
forms? The Supreme Court decision, Diamond vs. Chakrabarty, granted permission for just that 
(Ramsdale). To many it seems wrong that anyone can owu the rights to life. 
Future Directions 
Society ultimately needs to decide whether or not to pursue technology used for gene 
therapy and how it will be done. Many members of the scientific community believe the FDA 
and RAC are too restricting and discourage progress and advancements. Others are fearful that 
we are pursuing dangerous technologies too hastily. The public will need to decide for itself and 
make crucial decisions with little guidance or technical understanding. It is therefore impm1ant 
that we remain cautiously optimistic of technology that has the potential to revolutionize science 
and the way we approach treating genetic diseases. With so many variable outcomes, it is not 
unwise to consider what exactly such a powerful tool can bring about. 
Sustainability 
Introduction 
The science of sustainability involves "examining the interactions between human, 
environmental, and engineered systems to understand and contribute to solutions for complex 
challenges that threaten the future of humanity" (Clark). Our project aimed to impact this field 
by exploring a technology that has the potential to provide permanent solutions to debilitating 
genetic disorders. Because the T A LENs teclmology has a DNA binding domain attached to a 
DNA cleavage domain, the user is able to create a protein that can specifically target and create a 
double stranded break at any desired location. The ability to target an exact location allows for 
efficient and repeatable results. 
Sustainability and TALENs 
Since the TALEs used in the TALENs technology are designed after those found in the 
bacteria Xanthomonas, the TALENs teclmology is an efficient and accurate resource. The 
TALEs recognize DNA sequences based on RVDs, or two amino acids found within the longer 
repeat sequence from which they are coded. The genetic constructs that encode for the TALEs 
are produced by gene synthesis or modular assembly. These techniques are considered 
economical and are offered by many companies worldwide. It is therefore relatively easy to both 
create and obtain a library ofT ALEs. The organization Add gene, provides a plasmid kit 
containing a library ofT ALEs for the creation of customizable TAL ENs proteins. If the 
technology were to be fmther developed and validated, the creation of personalized TALENs 
would be a sustainable and desirable option. 
Manufacturability 
Our project involved exploring the potential ofTALENs for as a research tool. In order to 
ensure the integrity of our research and design project, the whole group was trained in good 
laboratory practices. This included keeping a detailed lab notebook and recording all data and 
results. Each member of the group analyzed data separately and then compared our findings. 
This helped ensure our data's accuracy, allowing us to ensure the integrity of our research. 
Keeping a detailed lab notebook will make the transition to manufacturing TALENs 
easier. If our project proves successful, eventually many different TALENs could be 
manufactured for gene therapy. This process will require a scale-up of our reactions to industrial 
levels. However, we have figured out the necessary concentrations for all our reactions, making 
this scale-up process easier and more feasible. 
Ethical Considerations 
Introduction 
The presidential commission for the study of bioethical issues developed a framework 
for addressing developing technologies such as gene therapy. Their main focus is on defining 
and applying the concept of responsible stewardship. Responsible stewardship is the 
responsibility of us all to act in a way that demonstrates concern for those that cannot represent 
themselves, such as children, the environment, or the future. This means ensuring we are fully 
aware of the risks and consequences of our actions on others. The commission's attitude towards 
addressing new technologies coincides with the Markkula Center for Applied Ethics' Framework 
for Thinking Ethically. 
The Center's approach begins with recognizing an ethical issue. The technology of gene 
therapy is a rapidly growing field that has the potential to prevent, treat, or cure genetic diseases. 
While this capability would allow for the treatment of horrible diseases such as cystic fibrosis or 
sickle cell anemia, if analyzed ethically, it may seem too good to be true. Gene therapy could 
provide a solution for those suffering from debilitating illnesses, but it could also allow people to 
alter undesirable traits or create designer babies. 
This idea raises many ethical questions. Should people be able to use genetic engineering 
to fix any trait or characteristic they are unsatisfied with? Where is the line drawn between 
someone that wants to use gene therapy to treat muscular cell dystrophy and someone that 
wishes they were genetically more capable of building muscle? The amazing capability of gene 
therapy to do good could quickly create unforeseen consequences and change the world in which 
we live. Parents would have the ability to alter their children, threatening their autonomy. 
According to Kantian ethics, because humans are autonomous agents and capable of making 
rational decisions, we all deserve dignity and respect. Autonomy gives everyone the right to 
make fully informed decisions about what happens to them and whether or not they want to 
participate in medical research. Altering a child's genetic information strips them of this choice. 
It is imp01tant that we recognize this and consider all possible outcomes and ethical responses. 
Although the gene therapy technology is nowhere near this advanced, by looking ahead we will 
be prepared if human experimentation becomes a possibility. 
Another question raised by the TALENs technology is: whether or not the ability to alter 
an organism's genome is playing God. If the technology continues to develop, it is likely to be 
used to treat human diseases. One argument states that human DNA should be off-limits to any 
tampering. We should not interfere with natmal selection or challenge our relationship with 
nature. If we allow pride or arrogance to cloud our judgment, we will lose reverence for life. An 
opposing argument believes that if we have the capability to cure honible diseases and ease 
potentially excruciating pain we have the responsibility to do so. The solution is in finding a 
balance between these two viewpoints. Using genetic engineering to alter a person's basic traits 
would be an abuse of the technology. The technology should be respected and used only to 
provide relief to those suffering from terrible illnesses. Acknowledging the sacredness and 
privilege of life will ensure that such a powerful tool will not be abused. 
Evaluation of Alternative Actions 
However, before we can realistically predict the development of gene therapy 
technologies, we need to ensure we have a deep understanding of the technology and its 
potential. Judgment cannot be made upon something that is not fully understood. Before 
committing to using TALENs as the chosen fmm of genetic engineering, a full analysis of 
competing technologies should be done in order to either discover a more ethical method or 
confirm that TALENs is the best option. Some of the competing technologies include 
retroviruses, zinc finger nucleases, and clustered regularly interspaced short palindromic repeats 
(CRISPR). TALENs outcompetes each of these technologies because it has less off target effects 
and is therefore the safest option. Off target effects refers to the genetic engineering tool (such as 
CRISPR) integrating at the wrong place in the genome. The consequences of this could be 
catastrophic because the technology could alter the genome in an uncontrolled manner, causing 
unknown effects on the genome. This occurred in a clinical trial that aimed to use retroviruses to 
treat severe combined immunodeficiency. In this trial, eleven children were given retroviral 
treatment, and nine recovered. However, of these nine children, four developed leukemia. It was 
discovered that the retroviruses had randomly integrated in the genome and turned on an 
oncogene, giving the kids cancer (Check). This highlights the need for the development of new 
approaches to gene therapy, specifically approaches which are safe and effective. 
From a utilitarian standpoint, T ALENs would be the obvious choice since it can 
accomplish what the other technologies do more effectively and in a less harmful manner. It 
provides the most hope for futthering the field of genetic engineering because it is targeted, 
efficient, and safe. 
Choice of C. elegans 
Our project aimed to demonstrate the safety and efficacy ofT ALENs by using the 
technology in a model organism, nematode C. elegans. This allowed for the study of the safety 
ofTALENs without experimentation in humans. Additionally, it will give the scientific 
community a better understanding of the technology, which will aid in determining regulation as 
to what T ALENs can and cannot be used for. 
Even though the use of a model organism prevents experimentation in humans, there are 
ethical concerns that must be taken into consideration when conducting research on living 
organisms. C. elegans are considered a model organism in the scientific community because they 
are one of the simplest systems to possess a nervous system, they can be frozen and thawed 
without damaging the organism, and they possess a quick reproduction rate (Comstock) . 
Therefore these nematodes are well studied and have been used in a variety of scientific 
experiments. However, there are some questions which must be addressed when conducting 
research on live organisms. These include: Will the experiment create an unnatural organism?, 
Who takes responsibility for the organisms used?, and How will the organisms be treated during 
the experimentation?. Our group carefully considered the implications of each of these questions 
before moving forward with our project. 
We detennined that yes, if successful, our project will create an urmatural organism. We 
used TALENs to mutate the lin-31 gene of C. elegans in order to learn more about cell fate 
specification in a RAS/MAPK signaling pathway. Therefore our project aimed to create C. 
elegans with a mutated signaling pathway. We detennined that the benefits gained from learning 
more about this signaling pathway and demonstrating the safety and efficacy ofTALENs 
outweighed the negative consequences of creating a mutated organism. 
Our group also addressed concerns of who would take responsibility for the organisms 
used in our experiment and how they would be treated. C. elegans are organisms that respond to 
stimuli and thus could be subject to inhumane laboratory practices. We addressed these concems 
by choosing an advisor who is well experienced in working with C. elegans. Our advisor has 
many years of experience in working with C. elegans and therefore was able to train us in proper 
handling of the organisms. Our group was trained to use C. elegans in a manner that minimizes 
the pain the organisms could experience and ensured that the organisms are not subjected to 
inhumane laboratory practices. Both our senior design group and our advisor ultimately took 
responsibility for the organisms used in the experiment and therefore committed ourselves to 
conducting our experiment in accordance to good lab techniques. 
C. elegans do have a nervous system and therefore could respond to pain caused by 
improper handling. However their nervous system is not highly developed and the level of pain 
would be minimal. Additionally, our project itself does not cause pain to the C. elegans as the 
TALENs mRNA is microinjected into the organisms and then the C. elegans ribosomes are used 
to produce the TALENs protein in vivo. Microinjection is a process that uses a very thin needle 
to inject mRNA into the C.elegans, the needle is so thin that it can barely be felt by the 
organisms. After microinjection, our experiment simply involved microscopically monitoring the 
development of the C. e/egans. This meant the C. elegans would experience minimal handling 
by our group. This allowed our group to ensure that the organisms were humanely treated and 
allowed our group to take responsibility for the organisms that we genetically altered. 
Future Implications 
Once the technology has been thoroughly assessed and all potential outcomes considered, 
a choice needs to be made about whether or not to continue developing the technology. The 
presidential commission for the study of bioethical issues created a method for approaching this 
decision making process called prudent vigilance. Prudent vigilance is the need to continue 
assessing the benefits and risks of a technology, both before, during, and after its development. 
As TALEN s is explored and implemented, experimental results will provide fmiher information 
about the efficacy and safety of the technology. Based off of this data, we can reevaluate the 
direction and goals of the technology and our project. In this matmer, scientific advancement will 
not be hindered but it will also not progress unchecked. Continuing to evaluate the ethical issues 
of a project as it develops ensures it will not take an undesirable direction and that the 
community stays informed and involved. 
Team and Organizational Ethics 
We upheld distributive justice by equally distributing the work between the members. 
One way we ensured that the work was distributed evenly was by everyone scheduling the same 
number of hours in the lab. We also tried to ensure that there were at least a few hours in which 
we were all present in the lab together, so that everyone could have a voice in the decisions. In 
this way we used technology to assist us in communication between our members. We each 
prepared our own lab notebooks as well as created a Google doc with the main experiments for 
the day so that each member knew what had been done, and what still needed to be done. For 
resolving any issues and working to uphold the common good of the group we established that if 
any conflict between members arose we would have a conversation and resolve the issue 
ourselves. If it could not be resolved between two members we would bring the other member of 
the group in to help address the problem. As a last resott we would speak with the advisor if an 
agreement could not be made between group members. 
In our project it was important that we analyzed the contributions that everyone made to 
the project, including our advisor and lab technician. Our team had the privilege of working with 
Dr. Miller, our advisor, and her employees to contribute to their research. When preparing our 
report we ensured that we gave credit to the other members of the lab for their contributions to 
the project, taking into account the justice and fairness of our project. All the reports were 
written and prepared by our team members. In addition we wanted to give credit to the previous 
researchers who provided the framework for us to do our work. Many of these researchers are 
included in our works cited, however two groups were especially impottant in our research. The 
first group was Carson Harms and Serena Lertkantitham who worked with TALENs in the Miller 
lab the previous year and laid the framework for our project. The second group was the Voytas 
lab group. The Voytas lab pioneered the TALENs technology and produced the kit we used. 
As demonstrated by our continuation of the project fi·om the previous year it was 
important that we maintained detailed documentation of our work. One of the virtues possessed 
by good scientists and engineers is the ability and dedication to habitually document their work. 
Our team aimed to be thorough in describing our work, so that future scientists and engineers 
could use our work. In our project the goal was to prove the efficacy and safety of TALENs, and 
this could only be achieved with thorough, detailed reports. In addition all results and data were 
accurate and true. No data was falsified or exaggerated to support our hypothesis. 
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Appendix 
Table 2. Modified Gannt Chart. 
Task description Start date Finish date Progress Resources 
Complete Lab Safety 9/30/14 10/2/14 completed 
School of Engineering Grant 10/2/14 10/10/14 completed 
Proposal 
Identify target Sequence and 10/20/14 10/20/14 completed TAL targeter 
RVD 
Make Repair plasmid 10/27/14 10/31/14 completed pLM 545 
Golden Gate reaction 1-1 10/27/14 completed RVD colonies 
Golden Gate reaction 1-2 10/27/14 11/18/14 completed RVD colonies 
Golden Gate reaction 2-1 10/27/14 RVD colonies 
Golden Gate reaction 2-2 10/27/14 11/7/14 completed RVD colonies 
Check 1-1 by colony PCR 10/31/14 1/23/14 completed Taq supplies 
Check 1-2 by colony PCR 10/31/14 Taq supplies 
Check 2-1 by colony PCR 10/31/14 Taq supplies 
Check 2-2 by colony PCR 10/31/14 11/7/14 completed Taq supplies 
Check 1-1 by sequencing 1/26/14 primers 
Check 1-2 by sequencing primers 
Check 2-1 by sequencing 1/26/14 primers 
Check 2-2 by sequencing 1/14/15 1/15/15 completed primers 
2nd Golden Gate for plasmid 1 golden gate primers 
and colonies 
2nd Golden Gate for plasmid 2 golden gate primers 
and colonies 
Check plasmid 1 
Check plasmid 2 
Make T ALENs mRNA for 1 
Make T ALENs mRNA for 2 
Inject mRNA 
Pick correct phenotypes 
Preform Cel-1 assay 
Sequence correct C. elegans 
Write Thesis lntro completed 
Write Thesis Body completed 
Complete Thesis completed 
First Draft of Presentation completed 
Final Presentation Complete completed 
